Mesoblast Share Price Today
(NASDAQ: MESO)

Name: Mesoblast Share Price Today (NASDAQ: MESO) - Mesoblast Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Mesoblast share price is $20.4 & ₹1,776.74 as on 5 Feb 2025, 2.30 'hrs' IST

$20.4

▲

0.34

(1.69%)

Market is closed - opens 8 PM, 05 Feb 2025

View live Mesoblast share price in Dollar and Rupees. Guide to invest in Mesoblast stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Mesoblast, along with analyst recommendations, forecasts, and comprehensive financials.

Mesoblast share price movements

Today's Low: $19.97
Today's High: $20.54
$20.40
2.11%
Downside
Day's Volatility :2.78%
Upside
0.68%
52 Weeks Low: $1.75
52 Weeks High: $22.00
$20.40
91.42%
Downside
52 Weeks Volatility :92.05%
Upside
7.27%

Mesoblast (MESO) Returns

Period	Mesoblast	Sector (Health Care)	Index (Russel 2000)
3 Months	129.78%	0.5%	0.0%
6 Months	241.16%	-2.3%	0.0%
1 Year	1008.29%	3.8%	0.0%
3 Years	144.63%	11.4%	-11.7%

Mesoblast (MESO) Key Statistics

in dollars & INR

Previous Close	$20.06
Open	$20.15
Today's High	$20.54
Today's Low	$19.97
Market Capitalization	$1.1B
Today's Volume	$296.7K
52 Week High	$22.0
52 Week Low	$1.75
Revenue TTM	$5.9M
EBITDA	$-56.1M
Earnings Per Share (EPS)	$-1.05
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-17.91%

How to invest in Mesoblast Stock (MESO) from India?

It is very easy for Indian residents to invest directly in Mesoblast from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Mesoblast stock in both Indian Rupees (INR) and US Dollars (USD). Search for Mesoblast or MESO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Mesoblast or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Mesoblast shares which would translate to 0.043 fractional shares of Mesoblast as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Mesoblast, in just a few clicks!

Returns in Mesoblast (MESO) for Indian investors in Rupees

The Mesoblast stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Mesoblast investment value today

Current value as on today

₹11,31,936

Returns

₹10,31,936

(+1.03K%)

Returns from Mesoblast Stock

₹10,27,072 (+1.03K%)

Dollar Returns

₹4,865 (+4.86%)

Indian investors sentiment towards Mesoblast (MESO)

-47%

Period: Jan 5, 2025 to Feb 4, 2025. Change in 30 Days versus previous period

Search interest for Mesoblast Stock from India on INDmoney has decreased by -47% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Mesoblast

Group One Trading, LP
0.20%
Morgan Stanley - Brokerage Accounts
0.14%
Summit X, LLC
0.12%
Susquehanna International Group, LLP
0.09%
Prosperity Wealth Management Inc
0.07%
Penbrook Management LLC
0.07%

Analyst Recommendation on Mesoblast

Buy

77%Buy

22%Hold

0%Sell

Based on 9 Wall street analysts offering stock ratings for Mesoblast(by analysts ranked 0 to 5 stars)

Based on 9 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Mesoblast Stock (MESO)

What analysts predicted

Downside of 28.92%

Target:

$14.50

Current:

$20.40

Insights on Mesoblast Stock (Ticker Symbol: MESO)

Price Movement
In the last 1 year, MESO stock has moved up by 1033.3%
Decreasing Revenue
Revenue is down for the last 5 quarters, 2.13M → 1.25M (in $), with an average decrease of 11.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 3 quarters, -16.26M → -27.70M (in $), with an average decrease of 35.2% per quarter

MESO Mesoblast Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$16.7M	↓ 3.57%
Net Income	$-89.8M	↑ 154.46%
Net Profit Margin	-537.01%	↓ 333.5%

	FY20	Y/Y Change
Revenue	$32.2M	↑ 92.3%
Net Income	$-77.9M	↓ 13.21%
Net Profit Margin	-242.38%	↑ 294.63%

	FY21	Y/Y Change
Revenue	$7.5M	↓ 76.81%
Net Income	$-98.8M	↑ 26.78%
Net Profit Margin	-1.3K%	↓ 1082.87%

	FY22	Y/Y Change
Revenue	$10.2M	↑ 36.95%
Net Income	$-91.3M	↓ 7.55%
Net Profit Margin	-894.59%	↑ 430.66%

	FY23	Y/Y Change
Revenue	$7.5M	↓ 26.54%
Net Income	$-81.9M	↓ 10.35%
Net Profit Margin	-1.1K%	↓ 197.12%

	FY24	Y/Y Change
Revenue	$5.9M	↓ 21.32%
Net Income	$-88.0M	↑ 7.41%
Net Profit Margin	-1.5K%	↓ 398.56%

	Q1 FY23	Q/Q Change
Revenue	$1.9M	↓ 2.07%
Net Income	$-18.6M	↓ 24.04%
Net Profit Margin	-959.26%	↑ 277.41%

	Q2 FY23	Q/Q Change
Revenue	$2.1M	↑ 10.31%
Net Income	$-21.9M	↑ 17.84%
Net Profit Margin	-1.0K%	↓ 65.47%

	Q3 FY23	Q/Q Change
Revenue	$1.7M	↓ 20.8%
Net Income	$-16.3M	↓ 25.77%
Net Profit Margin	-960.42%	↑ 64.31%

	Q4 FY23	Q/Q Change
Revenue	$1.7M	↑ 0.0%
Net Income	$-16.3M	↑ 0.0%
Net Profit Margin	-960.42%	↑ 0.0%

	Q1 FY24	Q/Q Change
Revenue	$1.3M	↓ 25.8%
Net Income	$-27.7M	↑ 70.31%
Net Profit Margin	-2.2K%	↓ 1243.92%

	Q2 FY24	Q/Q Change
Revenue	$1.3M	↑ 0.0%
Net Income	$-27.7M	↑ 0.0%
Net Profit Margin	-2.2K%	↑ 0.0%

	FY19	Y/Y Change
Profit	$1.4M	↓ 88.47%

	FY20	Y/Y Change
Profit	$6.8M	↑ 401.98%

	FY21	Y/Y Change
Profit	$-78.3M	↓ 1243.2%

	FY22	Y/Y Change
Profit	$-53.4M	↓ 31.83%

	FY23	Y/Y Change
Profit	$-47.4M	↓ 11.13%

	FY24	Y/Y Change
Profit	$-35.2M	↓ 25.84%

	Q1 FY23	Q/Q Change
Profit	$-11.4M	↓ 757.78%

	Q2 FY23	Q/Q Change
Profit	$-13.3M	↑ 16.78%

	Q3 FY23	Q/Q Change
Profit	$-8.0M	↓ 39.74%

	Q4 FY23	Q/Q Change
Profit	$-8.0M	↑ 0.0%

	Q1 FY24	Q/Q Change
Profit	$-9.6M	↑ 19.73%

	Q2 FY24	Q/Q Change
Profit	$-9.6M	↑ 0.0%

	FY19	Y/Y Change
Operating Cash Flow	$-57.8M	↓ 22.96%
Investing Cash Flow	$-1000.0K	↓ 13.27%
Financing Cash Flow	$71.6M	↑ 4.37%

	FY20	Y/Y Change
Operating Cash Flow	$-56.4M	↓ 2.47%
Investing Cash Flow	$-3.3M	↑ 227.3%
Financing Cash Flow	$137.0M	↑ 91.38%

	FY21	Y/Y Change
Operating Cash Flow	$-106.7M	↑ 89.27%
Investing Cash Flow	$-1.6M	↓ 49.68%
Financing Cash Flow	$114.5M	↓ 16.48%

	FY22	Y/Y Change
Operating Cash Flow	$-65.8M	↓ 38.34%
Investing Cash Flow	$-232.0K	↓ 85.91%
Financing Cash Flow	$-9.9M	↓ 108.62%

	FY23	Y/Y Change
Operating Cash Flow	$-63.3M	↓ 3.82%
Investing Cash Flow	$-194.0K	↓ 16.38%
Financing Cash Flow	$74.5M	↓ 854.83%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-14.2M	↓ 12.5%
Investing Cash Flow	$16.0K	↑ 0.0%
Financing Cash Flow	$-3.2M	↓ 108.3%

Mesoblast Technicals Summary

Sell

Neutral

Buy

Mesoblast is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Mesoblast (MESO) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Mesoblast	5.8%	241.16%	1008.29%	144.63%	4.7%
Biontech Se	-0.32%	51.19%	24.81%	-30.66%	288.02%
Regeneron Pharmaceuticals, Inc.	-6.9%	-37.55%	-28.89%	7.15%	74.63%
Vertex Pharmaceuticals Incorporated	16.87%	0.96%	13.03%	93.36%	95.94%
Alnylam Pharmaceuticals, Inc.	17.76%	5.53%	59.46%	84.7%	118.8%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Mesoblast	0.12	NA	0.0	-0.68	-0.18	-0.05	NA	0.42
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.64	16.64	1.08	44.92	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Mesoblast	Buy	$1.1B	4.7%	0.12	0.0%
Biontech Se	Buy	$29.7B	288.02%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$74.0B	74.63%	16.64	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$118.9B	95.94%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.0B	118.8%	NA	-15.86%

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

Organization	Mesoblast
Employees	73
CEO	Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Industry	Health Technology

Management People of Mesoblast

Name	Title
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)	Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director
Dr. Eric A. Rose M.D.	Chief Medical Officer & Executive Director
Mr. Andrew Chaponnel B.Com.	Interim Chief Finance Officer
Mr. Peter T. Howard B.Sc., L.L.B., LLB (Hons)	General Counsel & Corporate Executive
Dr. Paul J. Simmons BSc, Ph.D.	Scientific Advisor to the Chief Executive Officer
Ms. Geraldine Storton B.Sc., M.B.A., MMS	Head of Regulatory Affairs & Quality Management
Mr. Justin Horst B.S.	Head of Manufacturing
Dr. Fiona See Ph.D.	Senior VP & Head of Translational Research
Mr. Marcelo Santoro	Chief Commercial Officer
Ms. Niva Sivakumar B.Com., L.L.B.	Joint Company Secretary

Important FAQs about investing in MESO Stock from India :

What is Mesoblast share price today?

Mesoblast share price today stands at $20.40, Open: $20.15 ; Previous Close: $20.06 ; High: $20.54 ; Low: $19.97 ; 52 Week High: $22.00 ; 52 Week Low: $1.75.

The stock opens at $20.15, after a previous close of $20.06. The stock reached a daily high of $20.54 and a low of $19.97, with a 52-week high of $22.00 and a 52-week low of $1.75.

Can Indians buy Mesoblast shares?

Yes, Indians can invest in the Mesoblast (MESO) from India.

With INDmoney, you can buy Mesoblast at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Mesoblast at zero transaction cost.

How can I buy Mesoblast shares from India?

It is very easy to buy Mesoblast from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Mesoblast (MESO) be purchased?

Yes, you can buy fractional shares of Mesoblast with INDmoney app.

What are the documents required to start investing in Mesoblast stocks?

To start investing in Mesoblast, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.